Tenaya Therapeutics (TNYA) EBITDA Margin (2026)
Tenaya Therapeutics (TNYA) posted EBITDA Margin of 3971.89% for Q2 2026, up 55.46% on a QoQ basis from 8917.78% in Q1 2026.
Powered by 
Analysis
Tenaya Therapeutics (TNYA) EBITDA Margin (2026) Analysis & Trends
Tenaya Therapeutics has reported EBITDA Margin for 1 years, with the latest figure at 3971.89% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - | -25,827.14% |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 0.56% |
| 10 | Tenaya Therapeutics | 140.88 Mn | 140.88 Mn | - | -3,971.89% |